Emiko Ohki

412 total citations
22 papers, 324 citations indexed

About

Emiko Ohki is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Epidemiology. According to data from OpenAlex, Emiko Ohki has authored 22 papers receiving a total of 324 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 10 papers in Pulmonary and Respiratory Medicine and 6 papers in Epidemiology. Recurrent topics in Emiko Ohki's work include Lung Cancer Treatments and Mutations (9 papers), Lung Cancer Research Studies (6 papers) and Neuroendocrine Tumor Research Advances (4 papers). Emiko Ohki is often cited by papers focused on Lung Cancer Treatments and Mutations (9 papers), Lung Cancer Research Studies (6 papers) and Neuroendocrine Tumor Research Advances (4 papers). Emiko Ohki collaborates with scholars based in Japan, United States and Australia. Emiko Ohki's co-authors include Yuka Yamagishi, Hiroshige Mikamo, Satoshi Hashigaki, Koji Izumi, Tetsuhide Ito, Yutaka Endo, Asuka Tsuya, Hiroshi Nokihara, Narikazu Boku and Akinobu Yoshimura and has published in prestigious journals such as Annals of Oncology, Cancer Science and Journal of Thoracic Oncology.

In The Last Decade

Emiko Ohki

22 papers receiving 318 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Emiko Ohki Japan 10 168 148 71 69 36 22 324
M.B. Atkins United States 9 183 1.1× 87 0.6× 70 1.0× 24 0.3× 36 1.0× 22 360
Eun Young Kim South Korea 14 152 0.9× 170 1.1× 130 1.8× 60 0.9× 148 4.1× 38 517
Naoki Watanabe Japan 11 109 0.6× 175 1.2× 61 0.9× 35 0.5× 43 1.2× 36 318
Hemanth Kanakamedala United States 7 181 1.1× 195 1.3× 99 1.4× 53 0.8× 8 0.2× 19 384
Shohachi Suzuki Japan 12 240 1.4× 139 0.9× 38 0.5× 71 1.0× 248 6.9× 30 481
Yoshifumi Soejima Japan 8 309 1.8× 269 1.8× 95 1.3× 50 0.7× 43 1.2× 27 440
Tatsunori Kiriu Japan 13 199 1.2× 186 1.3× 119 1.7× 17 0.2× 44 1.2× 26 460
Ariane Laparra France 9 365 2.2× 146 1.0× 71 1.0× 59 0.9× 42 1.2× 21 503
Eduardo Huertas Argentina 9 208 1.2× 57 0.4× 50 0.7× 18 0.3× 95 2.6× 19 390
H Niitani Japan 10 316 1.9× 183 1.2× 188 2.6× 54 0.8× 63 1.8× 53 431

Countries citing papers authored by Emiko Ohki

Since Specialization
Citations

This map shows the geographic impact of Emiko Ohki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Emiko Ohki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Emiko Ohki more than expected).

Fields of papers citing papers by Emiko Ohki

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Emiko Ohki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Emiko Ohki. The network helps show where Emiko Ohki may publish in the future.

Co-authorship network of co-authors of Emiko Ohki

This figure shows the co-authorship network connecting the top 25 collaborators of Emiko Ohki. A scholar is included among the top collaborators of Emiko Ohki based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Emiko Ohki. Emiko Ohki is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Matsumoto, Nobuhiro, Kanae Togo, Naohiro Yonemoto, et al.. (2023). Real-world treatment response in Japanese patients with cancer using unstructured data from electronic health records. Health and Technology. 13(2). 253–262. 1 indexed citations
2.
Matsumoto, Nobuhiro, Kanae Togo, Naohiro Yonemoto, et al.. (2022). Developing Artificial Intelligence Models for Extracting Oncologic Outcomes from Japanese Electronic Health Records. Advances in Therapy. 40(3). 934–950. 9 indexed citations
3.
Endo, Yutaka, et al.. (2019). Treatment status and safety of crizotinib in 2028 Japanese patients with ALK-positive NSCLC in clinical settings. Japanese Journal of Clinical Oncology. 49(7). 676–686. 9 indexed citations
4.
Gemma, Akihiko, Masahiko Kusumoto, Yasuyuki Kurihara, et al.. (2018). Interstitial Lung Disease Onset and Its Risk Factors in Japanese Patients With ALK-Positive NSCLC After Treatment With Crizotinib. Journal of Thoracic Oncology. 14(4). 672–682. 31 indexed citations
5.
Endo, Yutaka, et al.. (2018). Real-world use of sunitinib in Japanese patients with pancreatic neuroendocrine tumors: results from a post-marketing surveillance study. Cancer Chemotherapy and Pharmacology. 83(1). 201–207. 6 indexed citations
6.
Nishio, Makoto, Dong‐Wan Kim, Yi‐Long Wu, et al.. (2017). Crizotinib versus Chemotherapy in Asian Patients with ALK-Positive Advanced Non-small Cell Lung Cancer. Cancer Research and Treatment. 50(3). 691–700. 45 indexed citations
7.
Okamoto, Isamu, Kazuhiko Nakagawa, Yuichiro Ohe, et al.. (2015). Safety of crizotinib in 892 Japanese ALK-positive advanced NSCLC patients: Interim report of post-marketing surveillance. Annals of Oncology. 26. vii37–vii37. 1 indexed citations
8.
Komatsu, Yoshito, et al.. (2015). Safety, efficacy and prognostic analyses of sunitinib in the post-marketing surveillance study of Japanese patients with gastrointestinal stromal tumor. Japanese Journal of Clinical Oncology. 45(11). 1016–1022. 10 indexed citations
9.
Igarashi, H, Takuji Okusaka, Tetsuhide Ito, et al.. (2013). Phase II Study of Sunitinib (SU) in Japanese Patients with Well-Differentiated Pancreatic Neuroendocrine Tumor (NET). Annals of Oncology. 24. ix82–ix82. 2 indexed citations
10.
Ohki, Emiko, Yuka Yamagishi, Yayoi Nishiyama, et al.. (2013). Fungal peritonitis associated with Curvularia geniculata and Pithomyces species in a patient with vulvar cancer who was successfully treated with oral voriconazole. The Journal of Antibiotics. 67(2). 191–193. 5 indexed citations
11.
Ohki, Emiko, Yuka Yamagishi, & Hiroshige Mikamo. (2013). Relationship between the clinical efficacy and AUC/MIC of intravenous ciprofloxacin in Japanese patients with intraabdominal infections. Journal of Infection and Chemotherapy. 19(5). 951–955. 4 indexed citations
12.
13.
Ito, Tetsuhide, Takuji Okusaka, Toshirou Nishida, et al.. (2012). Phase II study of sunitinib in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumor. Investigational New Drugs. 31(5). 1265–1274. 34 indexed citations
14.
Goto, Yasushi, Ikuo Sekine, Maki Tanioka, et al.. (2011). Figitumumab combined with carboplatin and paclitaxel in treatment-naïve Japanese patients with advanced non-small cell lung cancer. Investigational New Drugs. 30(4). 1548–1556. 29 indexed citations
15.
Ohki, Emiko, et al.. (2011). Antimicrobial efficacies of several antibiotics against uterine cervicitis caused by Mycoplasma genitalium. Journal of Infection and Chemotherapy. 18(3). 313–317. 31 indexed citations
16.
Yamagishi, Yuka, et al.. (2011). Investigation of the clinical breakpoints of piperacillin–tazobactam against infections caused by Pseudomonas aeruginosa. Journal of Infection and Chemotherapy. 18(1). 127–129. 9 indexed citations
17.
Okamoto, Isamu, Toshio Shimizu, Masaki Miyazaki, et al.. (2010). Feasibility study of two schedules of sunitinib in combination with pemetrexed in patients with advanced solid tumors. Investigational New Drugs. 30(2). 639–646. 8 indexed citations
18.
Ohki, Emiko, et al.. (2010). [Clinical application of azithromycin extended-release (ER) formulation to treat female sexually transmitted infection].. PubMed. 63(2). 93–104. 4 indexed citations
19.
Yamada, Kazuhiko, Masao Nakao, Hiroshi Nokihara, et al.. (2009). Phase I study of TLR9 agonist PF‐3512676 in combination with carboplatin and paclitaxel in patients with advanced non‐small‐cell lung cancer. Cancer Science. 101(1). 188–195. 18 indexed citations
20.
Yamagishi, Yuka, et al.. (2009). [Antifungal susceptibility of Candida species isolated from patient with invasive fungal peritonitis and investigation on clinical breakpoints of itraconazole].. PubMed. 62(5). 415–34. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by M.B. Atkins Breakdown of academic impact, for papers by Eun Young Kim Breakdown of academic impact, for papers by Naoki Watanabe Breakdown of academic impact, for papers by Hemanth Kanakamedala Breakdown of academic impact, for papers by Shohachi Suzuki Breakdown of academic impact, for papers by Yoshifumi Soejima Breakdown of academic impact, for papers by Tatsunori Kiriu Breakdown of academic impact, for papers by Ariane Laparra Breakdown of academic impact, for papers by Eduardo Huertas Breakdown of academic impact, for papers by H Niitani
Rankless by CCL
2026